Arthneeti
Latest: Concord Biotech Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
CB

Concord Biotech

Q1 FY27Pharmaceuticals & Biotechnology

Concord Biotech Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,548
Market cap₹16.4K Cr
P/E57.8
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 3 strong

RevenueGood growth
MarginMargins up
CapexCapex planned

The short version

Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid. Concord Biotech expects growth in FY27 to be better than historical growth rates, supported by business visibility and a robust product pipeline.

From Concord Biotech's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Good growth
  • Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid.
  • Current capacities show Unit 1 at ~78% utilization and Unit 3 at ~55%-higher than 20-25%, with plans to increase utilization.
  • Future growth relies on oncology and anti-infective products primarily manufactured in Unit 3, with oncology products generating higher revenue despite marginal capacity utilization change.
  • The company expects overall revenue improvement driven by new product launches, increased wallet share, and broader geographic growth.
  • Injectable facility, commercialized last year, is ramping up with sales starting in domestic markets and emerging markets expected next year.

2 more points from Concord Biotech's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Concord Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Concord Biotech is currently not adding capacity for scaling API revenues to INR2,200 crores in 5-6 years, utilizing existing facilities efficiently (Unit 1 at 78%, Unit 2 at 55%, Unit 3 has capacity for pipeline products).
  • Future API capacity expansion will be considered once Unit 3 utilization reaches 80-85%, leveraging available land (only 20-25% used on 160 acres) for brownfield expansion.
  • Potential capex may be required earlier if there’s a need for dedicated fermentation capacities for adjacencies like peptides, veterinary products, etc.
  • The company is exploring both organic and inorganic growth options, including adjacencies in the fermentation space and possible acquisitions.
  • Injectables facility recently commercialized, ramping up sales domestically and targeting emerging markets next year.

2 more points from Concord Biotech's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Related insights include: - Concord Biotech has strong business visibility in its pipeline for FY27 and beyond. - The company is working on multiple CDMO projects and expects revenue from this segment to increase from 1-2% to a double-digit contribution. - Several products, including oncology and anti-infectives, are in advanced stages or pipeline that will drive growth. - They continue to engage with innovator customers with a couple of projects progressing well and expected to be in advanced stage or closure by year-end.

2 more points from Concord Biotech's call on order book

Create a free account to keep reading this call

Concord Biotech — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Concord Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Q1 FY27 results?

Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid. Concord Biotech expects growth in FY27 to be better than historical growth rates, supported by business visibility and a robust product pipeline.

What is Concord Biotech share price analysis?

Concord Biotech currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 57.8 with a market cap of ₹16,438 Cr. Investors should review the full earnings analysis for detailed insights.

Is Concord Biotech planning capital expenditure?

Concord Biotech is currently not adding capacity for scaling API revenues to INR2,200 crores in 5-6 years, utilizing existing facilities efficiently (Unit 1 at 78%, Unit 2 at 55%, Unit 3 has capacity for pipeline products).

Keep Concord Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.